NEW YORK and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) — atai Impact, the philanthropic arm of atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), today announced the first cohort of the atai Fellowship Fund in Psychedelic Neuroscience (the “Fellowship Fund”) at Massachusetts General Hospital (“MGH”) Center for the Neuroscience of Psychedelics. The $2 million Fellowship Fund was announced in December…

Source

Previous articleIsraeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders
Next articleGilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments